afimkibart vs duvakitug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
afimkibart
Developed by Roche and partners
NCT04090411 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 study (N=246) in moderate-to-severe ulcerative colitis, with Week 14 clinical remission on the Mayo score as the primary endpoint. Although remission rates were numerically higher in all afimkibart dose groups (25.5%, 23.3%, 23.9%) than placebo (11.6%), the differences were not statistically significant (one-sided p-values 0.055–0.082; 90% confidence intervals crossed zero), so the primary efficacy comparison was not met. The well-controlled design is real evidence, but because the primary endpoint was missed, the trial does not rise to strong evidence of benefit.
Next expected readout: January 2027 · NCT06589986 (registry estimate)
Reported efficacy
Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14; Induction Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With Serious Adverse Events (SAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Chronic Period: Number of Participants With TEAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With SAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)): Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) (missed)
Result source: NCT04090411
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2028 · NCT07184996 (registry estimate)
Reported efficacy
Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)
Result source: NCT05499130
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | afimkibart | duvakitug |
|---|---|---|
| Clinical remission (induction) | 23.9% vs 11.6%+12.3 vs placeboNCT040904112 other results
| 47.8% vs 20.5%+27.3 vs placeboNCT054991303 other results
|
| Clinical remission (maintenance) | —Trial running · NCT06589986 | —Trial running · NCT07185009 |
| Clinical response (induction) | —Trial running · NCT06589986 | 69.6% vs 52.3%+17.3 vs placeboNCT054991303 other results
|
| Endoscopic improvement (induction) | 40.9% vs 18.6%+22.3 vs placeboNCT040904118 other results
| —Trial running · NCT07185009 |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT06589986 | —Trial running · NCT07185009 |
Clinical remission (induction)
- afimkibart
- 23.9% vs 11.6%+12.3 vs placeboNCT04090411
2 other results
- 23.3% vs 11.6% NCT04090411
- 25.5% vs 11.6% NCT04090411
- duvakitug
- 47.8% vs 20.5%+27.3 vs placeboNCT05499130
3 other results
- 36.2% vs 20.5% NCT05499130
- 23.9% vs 9.1% NCT05499130
- 29.8% vs 9.1% NCT05499130
Clinical remission (maintenance)
- afimkibart
- —Trial running · NCT06589986
- duvakitug
- —Trial running · NCT07185009
Clinical response (induction)
- afimkibart
- —Trial running · NCT06589986
- duvakitug
- 69.6% vs 52.3%+17.3 vs placeboNCT05499130
3 other results
- 73.9% vs 50% NCT05499130
- 80.9% vs 52.3% NCT05499130
- 83% vs 50% NCT05499130
Endoscopic improvement (induction)
- afimkibart
- 40.9% vs 18.6%+22.3 vs placeboNCT04090411
8 other results
- 36% vs 18.6% NCT04090411
- 37.5% vs 18.6% NCT04090411
- 50% vs 18.6% NCT04090411
- 38.3% vs 18.6% NCT04090411
- 37% vs 18.6% NCT04090411
- 39.3% vs 18.6% NCT04090411
- 40.4% vs 18.6% NCT04090411
- 38.1% vs 18.6% NCT04090411
- duvakitug
- —Trial running · NCT07185009
Corticosteroid-free remission (maintenance)
- afimkibart
- —Trial running · NCT06589986
- duvakitug
- —Trial running · NCT07185009
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. afimkibart: 5 of 5 rows · duvakitug: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | afimkibart | duvakitug |
|---|---|---|
| Endoscopic Remission responder rate · % of participants Induction | 10.2% (n=88) vs 7% (n=43) placebo450 mga,b,c,d,e NCT04090411 · Phase 2 show 8 more doses8.3% (n=24) vs 7% (n=43) placebo450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 21.4% (n=28) vs 7% (n=43) placebo450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 16% (n=25) vs 7% (n=43) placebo450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 10% (n=60) vs 7% (n=43) placebo150 mg NCT04090411 · Phase 2 7.1% (n=28) vs 7% (n=43) placebo150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 7.4% (n=27) vs 7% (n=43) placebo150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 19.1% (n=47) vs 7% (n=43) placebo50 mg NCT04090411 · Phase 2 11.9% (n=42) vs 7% (n=43) placebo50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 | 17.4% (n=46) vs 6.8% (n=44) placebo @ 14wk*900 mga,b,c,d,e NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted show 1 more dose17% (n=47) vs 6.8% (n=44) placebo @ 14wk*450 mg NCT05499130 · Phase 2b · monotherapy · converted to % from 8 Participants as posted |
| Dropout rate | 8.7%450 mgf NCT04090411 · Phase 2 show 9 more results—450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6.5%150 mg NCT04090411 · Phase 2 —150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2.1%50 mg NCT04090411 · Phase 2 —50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | 0%1800 mgf NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 8.5%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 19.6%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Discontinued due to AEs | 1.1%450 mgf NCT04090411 · Phase 2 show 9 more results—450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 1.6%150 mg NCT04090411 · Phase 2 —150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2.1%50 mg NCT04090411 · Phase 2 —50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | 0%1800 mgf NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.1%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 8.7%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Serious AEs | 4.4%450 mgf NCT04090411 · Phase 2 show 9 more results3.8%450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 13.8%450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 7.7%450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 1.6%150 mg NCT04090411 · Phase 2 0%150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 3.7%150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6.4%50 mg NCT04090411 · Phase 2 10.9%50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | 0%1800 mgf NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 13%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Most frequent reported AEs | 450 mgf headache 9.9% (placebo 2.2%) fatigue 5.5% (placebo 0%) pyrexia 5.5% (placebo 2.2%) NCT04090411 · Phase 2 show 9 more results450 mg (Induction) to 150 mg (Chronic) anaemia 11.5% (placebo 8.9%) colitis ulcerative 11.5% (placebo 0%) sars-cov-2 test positive 11.5% (placebo 0%) NCT04090411 · Phase 2 450 mg (Induction) to 450 mg (Chronic) blood creatine phosphokinase increased 10.3% (placebo 4.4%) anaemia 6.9% (placebo 8.9%) covid-19 6.9% (placebo 0%) NCT04090411 · Phase 2 450 mg (Induction) to 50 mg (Chronic) colitis ulcerative 23.1% (placebo 0%) sars-cov-2 test positive 15.4% (placebo 0%) anaemia 11.5% (placebo 8.9%) NCT04090411 · Phase 2 150 mg anaemia 8.1% (placebo 8.9%) injection site reaction 4.8% (placebo 2.2%) headache 3.2% (placebo 2.2%) NCT04090411 · Phase 2 150 mg (Induction) to 150 mg (Chronic) nausea 10% (placebo 2.2%) oropharyngeal pain 10% (placebo 2.2%) sars-cov-2 test positive 10% (placebo 0%) NCT04090411 · Phase 2 150 mg (Induction) to 50 mg (Chronic) sars-cov-2 test positive 18.5% (placebo 0%) colitis ulcerative 14.8% (placebo 0%) injection site reaction 11.1% (placebo 2.2%) NCT04090411 · Phase 2 50 mg nausea 6.4% (placebo 2.2%) urinary tract infection 6.4% (placebo 0%) anaemia 4.3% (placebo 8.9%) NCT04090411 · Phase 2 50 mg (Induction) to 50 mg (Chronic) colitis ulcerative 17.4% (placebo 0%) anaemia 8.7% (placebo 8.9%) blood creatine phosphokinase increased 6.5% (placebo 4.4%) NCT04090411 · Phase 2 500 mg IV arthralgia 12% colitis ulcerative 10% abdominal pain 6% NCT02840721 · Phase 2 · registry result, not featured evidence | 1800 mgf eczema 33.3% (placebo 0%) influenza 33.3% (placebo 2.2%) proteinuria 33.3% (placebo 0%) NCT05499130 · Phase 2b · monotherapy show 5 more results1800 mg abnormal uterine bleeding 14.3% (placebo 0%) insomnia 14.3% (placebo 0%) anaemia 0% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 900 mg nasopharyngitis 6.5% (placebo 6.5%) headache 2.2% (placebo 2.2%) vomiting 2.2% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy 900 mg headache 4.3% (placebo 2.2%) influenza 4.3% (placebo 2.2%) anaemia 2.2% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 450 mg headache 8.7% (placebo 2.2%) anaemia 6.5% (placebo 2.2%) nasopharyngitis 4.3% (placebo 6.5%) NCT05499130 · Phase 2b · monotherapy 450 mg nasopharyngitis 6.4% (placebo 6.5%) upper respiratory tract infection 6.4% (placebo 4.3%) vomiting 6.4% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2b versus Phase 2.
- cPopulation context differs: registered conditions differ.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
afimkibart
show 2 more results
show 8 more results
show 8 more results
show 8 more results
show 8 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
duvakitug
show 3 more results
show 3 more results
show 1 more result
show 1 more result
Crohn's Disease
Shared mechanism: TL1A · full Crohn's Disease pipeline
afimkibart
Developed by Roche and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05910528 (registry estimate)
No aligned efficacy figure on record for this race.
duvakitug
Developed by Teva Pharmaceutical Industries and partners
NCT05499130 · Phase 2b · completed
Randomized, double-blind, placebo-controlled dose-ranging basket study in UC and Crohn's disease. In UC the high dose separated from placebo on clinical remission (p=.003) and the low dose was borderline (p=.050); in Crohn's disease endoscopic response was 47.8% (high dose) and 26.1% (low dose) vs 13.0% placebo. The sponsor reports one-sided p-values at a 0.10 significance level, a lenient threshold, and each cohort was modest in size. A well-designed Phase 2b with a dose-dependent, partly borderline result is capped at moderate. Progressed to Phase 3.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: August 2028 · NCT07923383 (registry estimate)
Reported efficacy
Clinical remission (mMS) at week 14: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level. (met)
Result source: NCT05499130
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | afimkibart | duvakitug |
|---|---|---|
| Clinical remission (induction) | —Trial running · NCT06819891 | 54.3% vs 41.3%+13 vs placeboNCT054991303 other results
|
| Endoscopic response (induction) | —Trial running · NCT06819891 | 47.8% vs 13%+34.8 vs placeboNCT054991303 other results
|
| Clinical remission (maintenance) | —Trial running · NCT06819891 | —Trial running · NCT07184944 |
| Endoscopic response (maintenance) | —Trial running · NCT06819891 | —Trial running · NCT07184944 |
Clinical remission (induction)
- afimkibart
- —Trial running · NCT06819891
- duvakitug
- 54.3% vs 41.3%+13 vs placeboNCT05499130
3 other results
- 37% vs 26.1% NCT05499130
- 50% vs 41.3% NCT05499130
- 37% vs 26.1% NCT05499130
Endoscopic response (induction)
- afimkibart
- —Trial running · NCT06819891
- duvakitug
- 47.8% vs 13%+34.8 vs placeboNCT05499130
3 other results
- 26.1% vs 13% NCT05499130
- 39.1% vs 13% NCT05499130
- 34.8% vs 13% NCT05499130
Clinical remission (maintenance)
- afimkibart
- —Trial running · NCT06819891
- duvakitug
- —Trial running · NCT07184944
Endoscopic response (maintenance)
- afimkibart
- —Trial running · NCT06819891
- duvakitug
- —Trial running · NCT07184944
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
afimkibart: no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. afimkibart: 0 of 4 rows · duvakitug: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | duvakitug |
|---|---|
| Dropout rate | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 8.5%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 19.6%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Discontinued due to AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.1%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 8.7%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Serious AEs | 0%1800 mga NCT05499130 · Phase 2b · monotherapy show 5 more results0%1800 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 2.2%900 mg NCT05499130 · Phase 2b · monotherapy 13%450 mg NCT05499130 · Phase 2b · monotherapy 0%450 mg NCT05499130 · Phase 2b · monotherapy |
| Most frequent reported AEs | 1800 mga eczema 33.3% (placebo 0%) influenza 33.3% (placebo 2.2%) proteinuria 33.3% (placebo 0%) NCT05499130 · Phase 2b · monotherapy show 5 more results1800 mg abnormal uterine bleeding 14.3% (placebo 0%) insomnia 14.3% (placebo 0%) anaemia 0% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 900 mg nasopharyngitis 6.5% (placebo 6.5%) headache 2.2% (placebo 2.2%) vomiting 2.2% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy 900 mg headache 4.3% (placebo 2.2%) influenza 4.3% (placebo 2.2%) anaemia 2.2% (placebo 2.2%) NCT05499130 · Phase 2b · monotherapy 450 mg headache 8.7% (placebo 2.2%) anaemia 6.5% (placebo 2.2%) nasopharyngitis 4.3% (placebo 6.5%) NCT05499130 · Phase 2b · monotherapy 450 mg nasopharyngitis 6.4% (placebo 6.5%) upper respiratory tract infection 6.4% (placebo 4.3%) vomiting 6.4% (placebo 4.3%) NCT05499130 · Phase 2b · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
duvakitug
show 3 more results
show 9 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: afimkibart's landscape · duvakitug's landscape